Prof Jayesh Desai
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
501 Scholarly works
25 Projects
HIGHLIGHTS
2026
Journal article
Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial
DOI: 10.1038/s41698-025-01253-52026
Journal article
Real-World Trends and Outcomes for Localized High-Grade Soft Tissue Sarcoma: Insights from a Sarcoma Unit in Australia
DOI: 10.1111/ajco.700432026
Journal article
ID #672 A phase II study of continuous low dose panobinostat in paediatric patients with atypical teratoid rhabdoid tumours (ATRT).
DOI: 10.1093/neuped/wuag026.2712022
Research contracts (non-grants)
Cancer State-Wide Project (iPREDICT2 Study)
2021
Research Contracts
VCCC Alliance Program Agreement
2020
Research contracts (non-grants)
MoST Molecular Screening
2019
Journal article
A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2– positive metastatic breast cancer
DOI: 10.1158/2159-8290.CD-18-1151
RECENT SCHOLARLY WORKS
2026
Journal article
BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib cetuximab (EC) FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
DOI: 10.1200/jco.2026.44.17_suppl.lba35032026
Journal article
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.
DOI: 10.1158/1078-0432.CCR-26-05092026
Journal article
Re-sensitizing PD-1/PD-L1 relapsed/refractory solid tumors: Phase 1a results of IOS-1002, a LILRB1/2 and KIR3DL1 checkpoint inhibitor, in combination with pembrolizumab.
DOI: 10.1200/jco.2026.44.16_suppl.25012026
Journal article
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3.
DOI: 10.1016/j.annonc.2026.04.0172026
Journal article
Genomic Therapy Matching in Rare and Refractory Cancers
DOI: 10.1001/jamaoncol.2026.01272026
Journal article
C31-10 Analysis of Patient Reported Outcomes and Home Spirometry Ability to Detect Pneumonitis
DOI: 10.1093/ajrccm/aamag162.29772026
Journal article
Abstract CT303: Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy or combination therapy with cetuximab in previously treated metastatic CRC and PDAC: Results from a phase 1/2 study
DOI: 10.1158/1538-7445.am2026-ct303
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
A vaLue-based Person-Centric Enhanced Health Technology Assessment in CAncer Medicine (ALPACA)